Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Revvity Omics, |
RCV001782899 | SCV002017312 | likely pathogenic | not provided | 2020-12-18 | criteria provided, single submitter | clinical testing | |
| Invitae | RCV003766178 | SCV004687897 | uncertain significance | Tatton-Brown-Rahman overgrowth syndrome | 2023-09-20 | criteria provided, single submitter | clinical testing | This missense change has been observed in individual(s) with clinical features of Tatton-Brown-Rahman syndrome (PMID: 34092059). ClinVar contains an entry for this variant (Variation ID: 375884). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt DNMT3A protein function. This variant disrupts the p.Arg882 amino acid residue in DNMT3A. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 27317772, 28432085). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant is present in population databases (no rsID available, gnomAD 0.01%). This sequence change replaces arginine, which is basic and polar, with serine, which is neutral and polar, at codon 882 of the DNMT3A protein (p.Arg882Ser). |
| Database of Curated Mutations |
RCV000438614 | SCV000503767 | pathogenic | Acute myeloid leukemia | 2014-10-02 | no assertion criteria provided | literature only |